OPKO Health (NASDAQ:OPK) Stock Rating Lowered by Wall Street Zen

OPKO Health (NASDAQ:OPK) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities analysts also recently weighed in on OPK. JPMorgan Chase & Co. began coverage on OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating on the stock. Barrington Research decreased their price target on shares of OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $2.03.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.18 on Friday. OPKO Health has a 1-year low of $1.11 and a 1-year high of $1.95. The company has a current ratio of 3.97, a quick ratio of 3.52 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $895.70 million, a price-to-earnings ratio of -3.93 and a beta of 1.50. The stock’s fifty day simple moving average is $1.26 and its 200-day simple moving average is $1.35.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The firm had revenue of $148.50 million during the quarter, compared to the consensus estimate of $139.76 million. During the same period in the prior year, the business earned $0.01 EPS. The business’s revenue for the quarter was down 19.1% on a year-over-year basis. On average, sell-side analysts predict that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently made changes to their positions in OPK. Caitong International Asset Management Co. Ltd lifted its holdings in shares of OPKO Health by 1,056.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 39,232 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 35,841 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of OPKO Health in the 4th quarter valued at approximately $145,000. EP Wealth Advisors LLC acquired a new position in OPKO Health in the fourth quarter worth approximately $37,000. XTX Topco Ltd bought a new position in OPKO Health during the fourth quarter valued at approximately $432,000. Finally, Zacks Investment Management bought a new position in OPKO Health during the fourth quarter valued at approximately $27,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.